Boston Total Assets vs Deferred Long Term Liab Analysis

BSX Stock  USD 89.25  0.75  0.83%   
Boston Scientific financial indicator trend analysis is way more than just evaluating Boston Scientific Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Boston Scientific Corp is a good investment. Please check the relationship between Boston Scientific Total Assets and its Deferred Long Term Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Total Assets vs Deferred Long Term Liab

Total Assets vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Boston Scientific Corp Total Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Boston Scientific's Total Assets and Deferred Long Term Liab is -0.59. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Boston Scientific Corp, assuming nothing else is changed. The correlation between historical values of Boston Scientific's Total Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Boston Scientific Corp are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Total Assets i.e., Boston Scientific's Total Assets and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

-0.59
Relationship DirectionNegative 
Relationship StrengthVery Weak

Total Assets

Total assets refers to the total amount of Boston Scientific assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Boston Scientific Corp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.
Most indicators from Boston Scientific's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Boston Scientific Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
At this time, Boston Scientific's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 679.4 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.29 in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit8.1B8.7B9.9B10.4B
Total Revenue11.9B12.7B14.2B15.0B

Boston Scientific fundamental ratios Correlations

0.960.780.730.970.990.940.50.890.621.00.670.620.940.630.740.930.560.630.770.770.830.10.590.710.78
0.960.840.80.910.930.990.460.860.610.960.770.610.910.580.760.870.580.60.820.670.850.230.590.680.85
0.780.840.920.690.780.850.210.810.420.770.860.430.850.550.550.740.580.560.730.590.710.390.530.650.84
0.730.80.920.640.730.830.190.760.270.720.930.270.840.520.430.730.490.50.670.580.630.670.530.610.89
0.970.910.690.640.970.870.650.90.640.970.550.640.880.50.640.940.540.50.650.80.780.010.430.580.77
0.990.930.780.730.970.910.50.930.580.980.670.580.950.590.670.970.510.580.710.840.790.080.530.690.78
0.940.990.850.830.870.910.410.830.460.940.820.470.930.590.730.870.490.60.820.670.790.320.640.680.84
0.50.460.210.190.650.50.410.590.450.50.040.450.3-0.290.050.550.23-0.230.050.560.3-0.13-0.31-0.180.57
0.890.860.810.760.90.930.830.590.550.890.650.560.890.380.490.940.440.410.580.810.70.120.30.530.85
0.620.610.420.270.640.580.460.450.550.590.181.00.390.30.590.450.740.430.540.290.78-0.260.170.410.48
1.00.960.770.720.970.980.940.50.890.590.670.590.940.630.740.930.520.620.770.760.810.110.60.70.77
0.670.770.860.930.550.670.820.040.650.180.670.180.810.580.490.660.430.570.70.470.60.640.610.660.77
0.620.610.430.270.640.580.470.450.561.00.590.180.390.30.590.450.740.430.540.290.78-0.260.170.410.48
0.940.910.850.840.880.950.930.30.890.390.940.810.390.690.670.940.410.650.760.780.730.270.670.770.77
0.630.580.550.520.50.590.59-0.290.380.30.630.580.30.690.820.460.450.960.840.260.690.170.950.950.28
0.740.760.550.430.640.670.730.050.490.590.740.490.590.670.820.530.520.890.940.270.88-0.040.830.860.38
0.930.870.740.730.940.970.870.550.940.450.930.660.450.940.460.530.370.450.590.920.670.120.420.60.77
0.560.580.580.490.540.510.490.230.440.740.520.430.740.410.450.520.370.540.590.240.770.10.290.510.6
0.630.60.560.50.50.580.6-0.230.410.430.620.570.430.650.960.890.450.540.910.210.810.130.90.960.32
0.770.820.730.670.650.710.820.050.580.540.770.70.540.760.840.940.590.590.910.320.920.250.840.890.59
0.770.670.590.580.80.840.670.560.810.290.760.470.290.780.260.270.920.240.210.320.440.050.20.410.63
0.830.850.710.630.780.790.790.30.70.780.810.60.780.730.690.880.670.770.810.920.440.10.620.810.68
0.10.230.390.670.010.080.32-0.130.12-0.260.110.64-0.260.270.17-0.040.120.10.130.250.050.10.280.170.51
0.590.590.530.530.430.530.64-0.310.30.170.60.610.170.670.950.830.420.290.90.840.20.620.280.880.27
0.710.680.650.610.580.690.68-0.180.530.410.70.660.410.770.950.860.60.510.960.890.410.810.170.880.4
0.780.850.840.890.770.780.840.570.850.480.770.770.480.770.280.380.770.60.320.590.630.680.510.270.4
Click cells to compare fundamentals

Boston Scientific Account Relationship Matchups

Boston Scientific fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets30.6B30.8B32.2B32.5B35.1B36.9B
Short Long Term Debt Total10.3B9.5B9.5B9.3B9.5B10.0B
Other Current Liab2.8B2.9B2.8B2.5B3.0B3.1B
Total Current Liabilities4.9B3.7B4.3B3.8B4.9B5.2B
Total Stockholder Equity13.9B15.3B16.6B17.6B19.3B20.2B
Property Plant And Equipment Net2.4B2.5B2.7B2.8B3.3B3.5B
Net Debt10.1B7.8B7.5B8.4B8.6B9.1B
Retained Earnings(2.3B)(2.4B)(1.4B)(750M)819M860.0M
Accounts Payable542M513M794M862M942M989.1M
Non Current Assets Total25.9B24.1B25.9B26.7B28.6B30.1B
Non Currrent Assets Other735M545M563M707M680M714M
Net Receivables1.9B1.5B1.8B2.0B2.2B2.3B
Common Stock Shares Outstanding1.4B1.4B1.4B1.4B1.5B1.2B
Liabilities And Stockholders Equity30.6B30.8B32.2B32.5B34.9B36.6B
Non Current Liabilities Total11.8B11.8B11.3B11.1B10.7B6.2B
Inventory1.6B1.4B1.6B1.9B2.5B2.6B
Other Current Assets324M2.1B1.0B995M937M544.2M
Other Stockholder Equity15.8B17.5B17.7B18.0B18.4B10.0B
Total Liab16.7B15.5B15.6B14.9B15.6B8.6B
Property Plant And Equipment Gross2.4B2.5B2.3B2.4B6.8B7.1B
Total Current Assets4.7B6.7B6.3B5.8B6.5B3.3B
Accumulated Other Comprehensive Income270M207M263M269M49M51.5M
Short Term Debt1.4B13M261M20M531M417.5M
Intangible Assets7.9B5.9B6.1B5.9B6.0B4.9B
Other Liab3.0B2.2B2.1B1.8B2.1B1.9B
Other Assets(2M)4.6B3M2M(1M)950K
Long Term Debt8.6B9.1B8.8B8.9B8.6B5.6B
Good Will10.2B10.0B12.0B12.9B14.4B8.6B
Property Plant Equipment2.1B2.1B2.3B2.8B3.3B1.7B
Current Deferred Revenue144M138M208M220M266M333.1M
Net Tangible Assets(4.2B)9.4B(1.7B)11.7B13.4B14.1B
Retained Earnings Total Equity(2.3B)(2.4B)(1.4B)(750M)(862.5M)(905.6M)
Long Term Debt Total8.6B9.1B8.8B8.9B10.3B6.6B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.